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Abstract Oxidised low density lipoprotein (LDL) plays an
important role in the pathogenesis of atherosclerosis. Here we
demonstrate that mildly oxidised (mox) LDL engages the
GTPase Rho and its effector molecule p160 Rho-kinase to
induce phosphorylation of myosin light chain and of moesin
leading to platelet shape change. Pretreatment of platelets with
the selective Rho inhibitor C3-transferase from Clostridium
botulinum or with the Rho-kinase inhibitor Y-27632 blocked
mox-LDL-induced myosin light chain phosphorylation, moesin
phosphorylation and shape change. Mox-LDL did not induce an
increase in cytosolic Ca2 during shape change. We propose that
Rho/Rho-kinase inhibition could be a strategy for prevention of
the pathologic platelet activation during atherogenesis.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
Oxidative modi¢cation of low density lipoprotein (LDL)
plays an important role in the pathogenesis of atherosclerosis
[1]. Previous studies indicate that oxidatively modi¢ed LDL,
but not native LDL activates platelets, mildly oxidised LDL
(mox-LDL) being more active than heavily oxidised LDL
[2,3]. Oxidised LDL accumulates in lipid rich atherosclerotic
plaques. Upon plaque rupture it is exposed to circulating
platelets, leading to platelet activation and aggregation, intra-
vascular plug formation and potentially to stroke or myo-
cardial infarction [4,5]. The ¢rst response of platelets upon
activation by mox-LDL and other agonists is platelet shape
change [6]. Shape change is a contractile event, triggered by
myosin light chain (MLC) phosphorylation [7,8]. Phosphory-
lation induces a conformational change in MLC that enables
actin^myosin interaction and cell contraction. In order to
exert the mechanical tension required for shape change acto-
myosin bundles have to be anchored to the platelet mem-
brane. One actomyosin ¢lament/plasma membrane crosslinker
molecule is moesin. Upon phosphorylation on Thr-558, moe-
sin changes its conformation and is then capable of binding to
the plasma membrane via the N-terminus and to F-actin with
the C-terminus [9]. It was reported recently that MLC phos-
phorylation and shape change are regulated by two pathways
in platelets : Ca2/calmodulin-dependent myosin light chain
kinase (MLCK) and Rho-kinase [8,10]. Each of the two path-
ways can be activated independently of the other dependent
on the type and concentration of the platelet agonist [8].
Upon stimulation by GTP-bound Rho, Rho-kinase directly
phosphorylates MLC [11] and phosphorylates and thereby
inactivates MLC-phosphatase [12^14] to induce shape change
[8,10] or contraction of smooth muscle cells [15], ¢broblasts
[16] or endothelial cells [17,18]. Rho-kinase also phosphory-
lates and thereby activates the actin ¢lament/plasma mem-
brane crosslinker protein moesin [19,20]. Here we report
that (i) mox-LDL induces shape change and MLC phospho-
rylation via the Rho/Rho-kinase pathway but not via activa-
tion of the Ca2/calmodulin-dependent MLCK, and that (ii)
moesin is rapidly phosphorylated in a Rho-kinase-dependent
manner under these conditions.
2. Materials and methods
2.1. Materials
The Rho-kinase inhibitor Y-27632 was kindly provided by Akiko
Yoshimura, Yoshitomi Pharmaceuticals, Iruma-Shi, Saitama, Japan.
Anti-phospho-MLC antibody was a gift from J.M. Staddon, Eisai
Company, London, UK, anti-phospho-Thr-558 moesin antibody
was a gift from Kozo Kaibuchi, Nara Institute of Science and Tech-
nology, Ikoma, Japan. All materials not speci¢ed were purchased
from Sigma Chemical Co., Deisenhofen, Germany.
2.2. Isolation of platelets and measurement of platelet shape change
Human platelets were treated with acetylsalicylate, isolated by cen-
trifugation in the presence of apyrase as described [8] and resuspended
in a bu¡er containing 20 mM HEPES, 138 mM NaCl, 2.9 mM KCl,
1 mM MgCl2, and 0.6 U/ml apyrase. Platelet shape change was mea-
sured by recording the light transmission in a LABOR aggregometer
as described at a cell density of (2^4)U108/ml. Y-27632 was added at
the given concentration 30 min before stimulation followed by incu-
bation at 37‡C. In experiments using C3-transferase, platelets were
resuspended in bu¡er exactly as described [21] and incubated with
C3-transferase (400 Wg/ml) for 4 h at 37‡C. After incubation with
C3-transferase or vehicle, platelets were diluted to 109/ml for measure-
ment of shape change.
2.3. Preparation of mildly oxidised LDL
LDL was isolated in the continuous presence of EDTA as described
[3], dialysed at 4‡C using a N2-saturated bu¡er (pH 7.4) and then
stored at 4‡C in darkness under N2. All LDL concentrations are given
in terms of their protein content. Mox-LDL was prepared from
EDTA-free LDL by Cu2-triggered oxidation exactly as described [3].
2.4. Measurement of cytosolic Ca2 concentrations
For measurement of the cytosolic Ca2 concentration, washed
platelets were loaded with 4 WM FURA2-AM as described [8]) and
resuspended at a cell density of 2U108/ml. Ca2 was measured in a
thermostatically controlled (37‡C) chamber whilst stirring using a
Delta-Scan-1 double beam £uorescence spectrophotometer (Photon
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Technology International). Fluorescence measurement and calculation
of cytosolic Ca2 concentrations were performed as described [8].
2.5. Measurement of MLC and moesin phosphorylation
Platelets were stimulated as indicated and measurement of shape
change was carried out as described above. Portions of 50 Wl were
taken at the given time points, transferred to equal amounts of boiling
sample bu¡er (¢nal concentration 62.5 mM Tris, 3% SDS, 5% glyc-
erol, 5% 2-mercaptoethanol, 1 mM EDTA, pH 6.8) and boiled for
5 min. Proteins were then separated by SDS 12.5% PAGE (MLC
phosphorylation) or SDS 10% PAGE (moesin phosphorylation) and
electroblotted onto PVDF membranes using Mini Protean II electro-
phoresis cells (Bio-Rad). Membranes were incubated overnight with
anti-phospho-MLC antibody (1/500) or anti-phospho-moesin anti-
body (1/500) in Tris-bu¡ered saline containing 0.05% Tween 20,
washed three times, incubated for 1 h with horseradish peroxidase-
labeled goat anti-rabbit IgG antibody (Amersham) (1/7500 for detect-
ing phospho-MLC, 1/3000 for detecting phospho-moesin) in Tris-bu¡-
ered saline, washed three times and then developed with Luminol
solution (Pierce) and exposed to Kodak X-OMAT ¢lms. The amount
of phosphorylated MLC or phosphorylated moesin was determined
by densitometric analysis of the protein bands that reacted with anti-
phospho-MLC or anti-phospho-moesin antibody, using a Sharp XL-
325 densitometer and Pharmacia Image Master software. Phosphory-
lated MLC and phosphorylated moesin appeared as a single band of
20 kDa and 78 kDa, respectively. These 20 kDa and 78 kDa bands
were also detected by a mouse monoclonal antibody to total MLC
(Sigma, Deisenhofen, Germany) or moesin (Transduction Laborato-
ries, Hamburg, Germany). The range of linearity of the densitometric
measurements of phosphorylated myosin and moesin was determined
by a dilution series of protein samples of mox-LDL-stimulated plate-
lets (4^40 Wg of protein per lane).
3. Results
3.1. Rho-kinase inhibition blocks mox-LDL-induced shape
change
To investigate whether mox-LDL induces MLC phosphor-
ylation and platelet shape change via Rho/Rho-kinase or
Fig. 1. E¡ect of Rho-kinase inhibition on mox-LDL-induced platelet
shape change. a: Suspensions of washed human platelets were
placed in aggregometer cuvettes and incubated with the indicated
concentrations of Y-27632 for 30 min and then stimulated with
mox-LDL. Values are % of maximal shape change induced by mox-
LDL (10^40 Wg/ml) in the absence of Y-27632. Data are mean þ
S.E.M. of six experiments. b: Shape change tracings of platelets
stimulated with mox-LDL (30 Wg/ml) in the presence or absence of
Y-27632 (30 min, 40 WM). The decrease in light transmission togeth-
er with the disappearance of rapid oscillations is indicative of shape
change.
Fig. 2. Stimulation of MLC phosphorylation by mox-LDL during
platelet shape change. Suspensions of washed platelets were exposed
to mox-LDL (10^40 Wg/ml). In parallel to shape change MLC phos-
phorylation was determined by Western blot using a speci¢c anti-
body to phosphorylated MLC. The 20 kDa band detected by the
anti-phospho-MLC antibody was then analysed densitometrically. a:
Time course of MLC phosphorylation in mox-LDL-stimulated
platelets. Data are mean of three experiments þ S.E.M. b: Represen-
tative Western blot demonstrating the time course of MLC phos-
phorylation in mox-LDL-stimulated platelets. Equal protein load of
MLC was checked by Western blot using an antibody to total
MLC (phosphorylated and unphosphorylated MLC).
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Ca2/calmodulin-dependent MLCK we treated platelets with
the selective Rho-kinase inhibitor Y-27632 [22,23] as indicated
and then stimulated platelets with mox-LDL. Fig. 1a indicates
that Y-27632 at concentrations of 5 WM or higher signi¢cantly
reduced mox-LDL-induced shape change, and that 40 WM Y-
27632 induced a complete inhibition. Fig. 1b depicts represen-
tative shape change tracings of platelets stimulated with mox-
LDL in the presence or absence of Y-27632. These results
suggest that mox-LDL induces shape change via activation
of Rho-kinase.
3.2. Stimulation of MLC phosphorylation by mox-LDL during
shape change
Phosphorylation of the light chain enables myosin to inter-
act with and to slide against F-actin ¢laments in stress ¢bres,
which are the contractile organelles of non-muscle cells. To
measure mox-LDL-induced MLC phosphorylation during
platelet shape change we performed Western blots using a
speci¢c antibody to phosphorylated MLC. Fig. 2a indicates
that MLC phosphorylation in unstimulated platelets was very
low. In mox-LDL-treated platelets MLC phosphorylation was
elevated about 18-fold after 20 s of stimulation; then MLC
phosphorylation fell to a plateau before it reached almost
baseline levels after 5 min. Fig. 2b depicts representative
Western blots demonstrating the time course of MLC phos-
phorylation and equal protein load of MLC. Our data indi-
cate that mox-LDL like other platelet activators induces shape
change by a rapid and reversible increase in MLC phosphor-
ylation.
3.3. Mox-LDL induces MLC phosphorylation via
Rho/Rho-kinase
As inhibition of Rho-kinase prevents mox-LDL-induced
shape change, inhibition of Rho or Rho-kinase should also
block MLC phosphorylation under these conditions. Conse-
quently we treated platelets with C3-transferase from Clostri-
dium botulinum to inhibit Rho speci¢cally [24] or with the
Rho-kinase inhibitor Y-27632. Thereafter we stimulated plate-
lets with mox-LDL for di¡erent time periods as indicated, and
then measured MLC phosphorylation. Fig. 3 indicates that
inhibition of Rho as well as inhibition of Rho-kinase com-
pletely blocked mox-LDL-induced MLC phosphorylation, in-
dicating that mox-LDL activates Rho/Rho-kinase to induce
MLC phosphorylation and shape change.
3.4. Mox-LDL induces moesin phosphorylation during platelet
shape change
The actin ¢lament/plasma membrane crosslinker protein
moesin is phosphorylated during platelet activation by throm-
bin [9]. Therefore moesin could also be phosphorylated upon
platelet activation by mox-LDL. To address this question we
measured moesin phosphorylation in platelets stimulated with
Fig. 3. E¡ect of Rho/Rho-kinase inhibition on mox-LDL-induced
MLC phosphorylation. Platelet suspensions were placed in aggrego-
meter cuvettes and incubated with (a) C3-transferase (4 h, 400 Wg/
ml) or (b) Y-27632 (30 min, 40 WM) and stimulated with mox-LDL
(10^80 Wg/ml). MLC phosphorylation was determined in parallel to
shape change. Aliquots of the platelet suspensions were transferred
to boiling sample bu¡er for detection of MLC phosphorylation by
Western blot using a speci¢c antibody to phosphorylated MLC.
Blots are representative of three experiments. C3-transferase cross-
reacted with the antibody to phosphorylated MLC. The asterisk in-
dicates a lane where only C3-transferase was loaded (50 Wg) to dem-
onstrate the crossreaction.
Fig. 4. Stimulation of Thr-558 moesin phosphorylation by mox-
LDL during shape change. Suspensions of washed platelets were ex-
posed to mox-LDL (10^40 Wg/ml). In parallel to shape change Thr-
558 moesin phosphorylation was determined by Western blot using
a speci¢c antibody to phosphorylated Thr-558. a: Time course of
moesin phosphorylation during mox-LDL-induced shape change.
Data are means of three experiments þ S.E.M. b: Representative
Western blot indicating moesin phosphorylation during mox-LDL-
induced shape change. Equal protein load of moesin was checked
by Western blot using an antibody to total moesin (phosphorylated
and unphosphorylated moesin).
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mox-LDL, using a speci¢c antibody to moesin phosphory-
lated on Thr-558. As indicated by Fig. 4 we found that moesin
is partly phosphorylated in unstimulated platelets similar as
described previously [9]. During shape change induced by
mox-LDL, moesin phosphorylation was elevated about
5-fold within a few seconds of stimulation and remained ele-
vated for at least 5 min after stimulation (Fig. 4a). Fig. 4b
depicts representative Western blots demonstrating the time
course of moesin phosphorylation and equal protein load of
moesin. Mox-LDL-induced moesin phosphorylation could be
blocked by inhibition of Rho or Rho-kinase. Fig. 5a shows
moesin phosphorylation in cells pretreated with C3-transfer-
ase and then stimulated with mox-LDL. Fig. 5b depicts moe-
sin phosphorylation in platelets pretreated with Y-27632 and
then stimulated with mox-LDL. Both inhibitors markedly re-
duced mox-LDL-induced moesin phosphorylation. Our data
show for the ¢rst time that mox-LDL induces moesin phos-
phorylation via Rho/Rho-kinase during platelet shape change.
3.5. mox-LDL does not increase cytosolic Ca2+ during platelet
shape change
MLC phosphorylation is regulated by Ca2/calmodulin-de-
pendent MLCK or by Rho-kinase during platelet shape
change [8,10]. To investigate whether also Ca2/calmodulin-
dependent MLCK at least partly contributes to mox-LDL-
induced MLC phosphorylation we measured cytosolic Ca2
concentrations. As indicated in Fig. 6, mox-LDL at the con-
centrations used (10^100 Wg/ml) did not increase the cytosolic
Ca2 concentration. Under the same conditions thrombin (1
U/ml) induced a signi¢cant elevation of the cytosolic Ca2.
These data indicate that MLCK is most likely not involved in
mox-LDL-induced MLC phosphorylation in human platelets.
4. Discussion
In the present study we report for the ¢rst time that mox-
LDL induces platelet shape change via activation of Rho/
Rho-kinase. Upon stimulation with mox-LDL, Rho-kinase
induces MLC phosphorylation allowing the myosin head in-
teracting with actin to enable the formation of contractile
actin/myosin bundles and in parallel phosphorylates moesin
which then mediates the interaction of the newly formed bun-
dles with the plasma membrane. Both processes are likely
required for induction of shape change. It has been found
in this regard that phosphorylation of MLC precedes shape
change [25] and that moesin-Thr-558 is phosphorylated during
platelet activation by thrombin [9]. Our results further show
that Ca2/calmodulin-dependent MLCK is very likely not ac-
tivated during mox-LDL-induced shape change, because
under the conditions described mox-LDL did not increase
the cytosolic Ca2 concentration. On the other hand it could
be speculated that basal activities of MLCK could be su⁄-
cient to induce MLC phosphorylation leading to shape change
when MLC-phosphatase is phosphorylated and inhibited by
Rho-kinase.
It is well documented that activation of platelets by mox-
LDL is not a toxic e¡ect, but is initiated by activation of
receptor-mediated signal pathways [26]. In particular we re-
ported recently that mox-LDL activates the LPA (lysophos-
phatidic acid) receptor to induce platelet shape change [26].
Therefore LPA should activate platelets by the same signal
pathways as mox-LDL. Indeed we found that LPA induces
MLC and moesin phosphorylation in a Ca2-independent
manner via Rho/Rho-kinase (unpublished observation). Fur-
thermore we showed recently that mox-LDL engages Rho/
Rho-kinase to increase endothelial permeability [18]. This
means that the Rho/Rho-kinase pathway could contribute
to the pathologic platelet activation and to endothelial injury
during cardiovascular diseases. We therefore propose that in-
hibition of Rho-kinase or Rho could be a preventive or ther-
apeutic strategy to treat cardiovascular diseases.
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